Latest Conference Articles

Looking to explore the city between Fall Clinical sessions or to extend your stay? Check out this top 10 list of the best Las Vegas has to offer in October.

One of the largest dermatology meetings of the year kicks off today with an exciting line up of expert perspectives and clinical pearls. Here's what you can expect.

Click here to answer if you're attending IDS 2023.

One of the many minds behind innovative Fall Clinical Dermatology sessions gives a sneak peek of the top 5 things to look forward to during this year's meeting.

Click here to answer if you're attending Fall Clinical.

Among the many sessions to be held at the 2023 Fall Clinical Dermatology Conference in Las Vegas, Nevada, several Dermatology Times® Editorial Advisory Board members are preparing to share their knowledge and insights.

Kwatra presented the abrocitinib data at EADV 2023.

The expanded study data correlates with the safety and efficacy of ruxolitinib cream in patients with atopic dermatitis.

After maintenance treatment with sonelokimab dosed every 4 weeks, 57% of patients achieved HiSCR75 at week 24.

The continued reduction in WI-NRS was seen in patients who remained in the study through week 52.

UCB presented data from the BE HEARD I and BE HEARD II phase 3 studies at this year's EADV Congress.

Sanofi’s phase 3 program for amlitelimab in atopic dermatitis will start in early 2024.

Almirall presented new data on lebrikizumab at EADV related to clinical improvements and clinically-meaningful treatment responses among patients with atopic dermatitis.

At week 8, 65.3% of roflumilast-treated patients achieved a clinically significant reduction in itch.

AbbVie announced the 24- and 52-week data at EADV 2023.

Patients and their families experienced significant improvements to well-being with tildrakizumab use in as little as 16 weeks.

New data from ADORING 1 and ADORING 2 show a rapid reduction in pruritus relief as early as 24 hours after the first application.

Longer-term use of povorcitinib demonstrated further improvement in total body and facial repigmentation.

Clinical response was maintained at 73.2% for PASI-75 in POETYK PSO long-term extension trial.

Kristina Collins, MD, delves into the importance of being present in the moments you have control over and making self-care a priority on the road.

Discover the top pearls and takeaways from sessions at Maui Derm NP+PA Fall 2023 in Asheville, North Carolina.

New and emerging therapies to treat a variety of skin conditions were presented by George Martin, MD, and Ted Rosen, MD.

The hair guru explains how he opened up the first dermatology practice dedicated to hair, pearls from his session, innovative therapies, and research he has recently submitted.

Colleen Cotton, MD, does a deep dive on pediatric atopic dermatitis and explains the importance of timing and conversations with patients about different treatments.

Trifarotene emerges as an effective and well-tolerated solution for acne across diverse populations.

The distribution of eyebrow and eyelash hair loss in relation to the severity of scalp hair loss remains underexplored, and this study established baseline characteristics.

Matthew Zirwas, MD, addressed solutions to the toll consistent handwashing, sanitizing, and wearing gloves can take on hands.

Researchers found that continued use of once-daily subantibiotic dose oral doxycycline 40 mg modified-release capsules significantly reduced the relapse rate and inflammatory lesion counts in patients with moderate-to-severe rosacea.